Search clinical trials for: Targinact® (oxycodone/naloxone)

Total 76 results

Mundipharma CVA

Unknown

A Non-interventional, Observational Study for Quality of Life (Overall Health Assessment) in Patients With Chronic Severe Pain During Targinact® Treatment

Chronic Severe Pain

Belgium
Mundipharma CVA

Completed

A Non-interventional, Observational Study for Targinact® Treatment in Patients With Severe Pain.

Severe Pain

Belgium
Mundipharma CVA

Completed

A Non-interventional, Observational Study for Targinact® Treatment in Patients With Chronic Severe Pain

Chronic Severe Pain

Belgium
University of Edinburgh

Completed

A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery (TACS)

Postoperative Pain | Postoperative Nausea and Vomiting

United Kingdom
Mundipharma Research GmbH & Co KG

Completed

OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects

Chronic Osteoarthritis

Spain, Belgium, Finland, Czechia, Germany, Hungary
University Hospital Inselspital, Berne

Completed

Early Postoperative Administration of Oxycodone +/- Naloxone and Duration of Epidural Analgesia

Epidural Analgesia | Radical Cystectomy | Postoperative Pain Management | Oral Oxycodone With/Without Naloxone | Return of the Bowel Function

Switzerland
Mundipharma Research GmbH & Co KG

Completed

A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain

Subjects With Moderate to Severe, Chronic Nonmalignant Pain
University of British Columbia
Vancouver Coastal Health; International Collaboration on Repair Discoveries; Purdue...

Completed

Targin® for Chronic Pain Management in Patients With Spinal Cord Injury

Chronic Pain

Canada
Mundipharma SAS

Terminated

Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients (OXN3505)

Pain | Constipation

France
Mario Negri Institute for Pharmacological Research

Completed

GREAT - Good Response With Appropriate Treatment

Neoplasms | Cancer Pain

Italy
Mundipharma Research GmbH & Co KG

Completed

A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy

Pain | Constipation

United Kingdom
Purdue Pharma LP

Completed

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

Low Back Pain

United States, Poland, Czech Republic, Italy
Ullevaal University Hospital
Mundipharma AB

Completed

A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy

Postoperative Pain | Opioid Induced Constipation

Norway
Purdue Pharma LP

Completed

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
Mundipharma Research GmbH & Co KG

Completed

A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain

Pain | Cancer | Constipation

United Kingdom
Kuopio University Hospital

Completed

Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery (oksineukir)

Constipation

Finland
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

Targin for Non-cancer Pain

Non Cancer Pain

China
Mundipharma Korea Ltd

Completed

A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients (TOP)

Cancer

Korea, Republic of
Mundipharma Korea Ltd

Completed

An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY)

Chronic Pain

Korea, Republic of
Mundipharma Pharmaceuticals B.V.

Completed

Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain

Pain

Belgium
Mundipharma Research GmbH & Co KG

Completed

Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related Constipation

Pain
Kuopio University Hospital
Admescope Ltd

Active, not recruiting

Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section (oksisektio)

Pain, Postoperative | Constipation

Finland
Mundipharma Korea Ltd

Completed

PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer Pain (PROBE)

Cancer

Korea, Republic of
Mundipharma Korea Ltd

Completed

An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal Disorders (TALENT)

Spinal Disorders
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain

Pain | Cancer

China
Kati Järvelä

Completed

A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery

Postoperative Pain | Opioid Related Disorders

Finland
Mundipharma Research GmbH & Co KG

Completed

OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)

Pain | Interstitial Cystitis | Painful Bladder Syndrome

Poland, Germany, Hungary, Czechia, United Kingdom
Purdue Pharma LP

Completed

Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
Mundipharma Research GmbH & Co KG

Completed

A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain

Parkinson's Disease With Severe Pain

United Kingdom, Spain, Germany, Hungary, Czech Republic, Poland, Romania
Mundipharma Research GmbH & Co KG

Completed

Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms

Moderate to Severe Idiopathic RLS With Daytime Symptoms

Spain, Sweden, Germany
Medlab Clinical
George Clinical Pty Ltd; WriteSource Medical Pty Ltd

Not yet recruiting

NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers

Cancer Related Pain
Mundipharma Korea Ltd

Completed

A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Cancer

Korea, Republic of
Mundipharma Pharmaceuticals B.V.

Completed

Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain

Pain

Netherlands
Mundipharma Research GmbH & Co KG

Completed

A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy

Moderate to Severe Pain Due to Diabetic Polyneuropathy

Germany
Mundipharma Oy

Completed

OXN PR Compared to OXY PR in Subjects With Postoperative Pain After Knee Arthroplasty (OXN4505)

Post Operative Pain

Finland
IRCCS Policlinico S. Matteo

Withdrawn

Treatment of Chronic Pain From Osteoarthritis

Chronic Pain

Italy
Napp Pharmaceuticals Limited

Completed

A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis

Osteoarthritis | Back Pain

United Kingdom
Indivior Inc.

Completed

Transfer of Subjects From Subutex/Suboxone to RBP-6300

Opioid Related Disorder

Austria, Czech Republic, Germany, Sweden
Artoss Inc.

Recruiting

Prospective Registry to Evaluate Outcomes of NanoBone® Bone Graft in Acute Trauma (ARTIST)

Fractures, Bone

United States
Wake Forest University Health Sciences

Withdrawn

Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films

Opioid Use
Mundipharma Research GmbH & Co KG

Completed

Oxycodone-naloxone in Relieving Opioid-related Constipation

Pain
Grünenthal GmbH

Completed

Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.

Back Pain | Low Back Pain | Neuropathic Pain

Germany, Spain, Austria, Italy
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

OTR Tablet 10 mg Fasted-state Bioequivalence Study

Chronic Pain

China
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

OTR Tablet 40 mg Fed-state Bioequivalence Study

Chronic Pain

China
Indivior Inc.

Completed

Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)

Drug Abuse | Opiate Dependence | Opiate-related Disorders
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

OTR Tablet 40 mg Fasted-state Bioequivalence Study

Chronic Pain

China
Mundipharma Research GmbH & Co KG

Completed

To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain

Non-malignant Pain | Malignant Pain

Germany
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

Pharmacokinetic (PK) Study of OxyNorm Injections in Chinese Patient

Pain

China
Purdue Pharma LP

Completed

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Healthy

United States
Centre for Addiction and Mental Health
University of Toronto

Completed

Abuse Liability of Controlled-Release Oxycodone Formulations

Substance-Related Disorders

Canada

3

Subscribe